Back to Results
First PageMeta Content
Astellas Pharma / Pharmaceutical industry in India / Micafungin / Pharmaceutical industry / Tamsulosin / Regadenoson / Chemistry / Pharmaceutical sciences / Pharmacology


Annual Report 2010 For the Year Ended March 31, 2010 Contents 06
Add to Reading List

Document Date: 2010-10-25 00:58:50


Open Document

File Size: 2,27 MB

Share Result on Facebook

Company

Profile Profile Astellas Pharma Inc. / Astellas Group / Astellas Pharma Inc. / /

Continent

Asia / Europe / Americas / /

Country

Japan / United States / /

Currency

USD / EUR / /

Event

Dividend Issuance / Reorganization / /

IndustryTerm

in-license products / existing and new products / mainstay products / protein drug technologies / growth products / treatment for the functional symptoms / research-oriented global pharmaceutical / pharmaceuticals / overactive bladder technologies / communications slogan / manufacturing costs / ethical pharmaceutical products / main growth products / well-balanced global business network / growth product / treatment for migraine / ethical pharmaceutical / pharmaceutical products / business operations / pharmaceutical / well-balanced global sales network / business infrastructure / sales network / prostate cancer treatment / focused on establishing a solid global business infrastructure / /

Person

Masafumi Nogimori / /

Position

leader / Major / global category leader / President & CEO / /

Product

Vesicare / Eligard / Prograf / Harnal / /

Technology

drug discovery / transplantation / protein drug technologies / overactive bladder technologies / /

SocialTag